- Home
- /
- Treatment
- /
- Page 119
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Girentuximab | Renal cancer | Heidelberg Pharma AG;101 Schriesheimer Stra�e;Ladenburg | March 22, 2001 | |
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody | Renal cancer | Wilex Biotechnology GmbH;Grillparzerstrasse 10B, 81675 Munich; | March 22, 2001 | |
Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7 | Recurrent respiratory papillomatosis | StressGen Biotechnologies, Inc. is now Nventa;Nventa Biopharmaceuticals Corporation, 6055 Lusk Boulevard;San Diego, California, 19426 | March 19, 2001 | |
Vasoactive intestinal peptide | Acute Respiratory Distress Syndrome | mondoBIOTECH;Europark, FL - 9490 Vaduz; | March 9, 2001 | |
Coenzyme Q10 | Huntington disease | Integrative Therapeutics, Inc.;825 Challenger Drive;Green Bay, Wisconsin, 54311 | March 5, 2001 | |
Eculizumab | Idiopathic membranous glomerular nephropathy | Alexion Pharmaceuticals, Inc.;352 Knotter Drive;Cheshire, Connecticut, 06410 | March 5, 2001 | |
Busulfan | Intrathecal therapy for neoplastic meningitis | SuperGen, Inc.;4140 Dublin Boulevard;Dublin, California, 94568 | March 5, 2001 | |
Docosahexanoic acid-paclitaxel | Hormone-refractory prostate cancer | Luitpold Pharmaceuticals, Inc.;One Luitpold Drive;Shirley, New York, 11976 | March 5, 2001 | |
Recombinant Human Alpha-Fetoprotein (rhAFP) | Myasthenia gravis Myasthenia gravis | Alpha Cancer Technologies, Inc.;MaRS Discovery District, South Tower, 200-101 College St.;Toronto, Ontario | February 22, 2001 | |
Medroxyprogesterone acetate | Immune thrombocytopenic purpura | ZaBeCor Pharmaceutical Company, LLC;821 Westview Street;Philadelphia, Pennsylvania, 19119 | February 22, 2001 | |
B Lymphocyte Stimulator | Common variable immunodeficiency | Human Genome Sciences, Inc.;9410 Key West Avenue;Rockville, Maryland, 20850 | February 21, 2001 | |
Pyruvate | Interstitial lung disease | Cellular Sciences, Inc;84 park Avenue, P.O. Box 968;Flemington, New Jersey, 08822 | February 21, 2001 | |
Nitroprusside | Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage | Thomas, MD, Jeffrey Evan;Thomas Jefferson University and Wills Neurosensory, 834 Walnut Street, Suite 650;Philadelphia, Pennsylvania, 19107 | February 21, 2001 | |
Alendronate disodium | Gaucher disease | Richard J. Wenstrup, M.D.;Division of Human Genetics, Children's Hospital Research Foundation;Cincinnati, Ohio, 45229 | February 13, 2001 | |
Virulizin | Pancreatic cancer | ZOR Pharmaceuticals, LLC;100-A Eastwood Center Drive, Suite 118;Wilmington, North Carolina, 28403 | February 1, 2001 | |
Imatinib | Chronic myeloid leukemia | Novartis Pharmaceuticals Corporation;59 Route 10;East Hanover, New Jersey, 07936 | January 31, 2001 | |
Novel Acting Thrombolytic (NAT) | Peripheral arterial occlusion (PAO) | Nuvelo, Inc. Inc.;201 Industrial Road, Suite 310;San Carlos, California, 94070 | January 26, 2001 | |
Synthetic Human Parathyroid Hormone 1-34 | Hypoparathyroidism | Rare Disease Therapeutics, Inc.;2550 Meridian Blvd;Nashville, Tennessee, 37217 | January 26, 2001 | |
MTC-DOX for Injection | Hepatocellular Carcinoma | FeRx Incorporated;4330 La Jolla Village Drive, Suite #250;San Diego, California, 92122 | January 3, 2001 | |
N-acetylcysteinate Lysine | Cystic fibrosis | Galephar Pharmaceutical Research, Inc.;Road 198, No. 100 km. 14.7, Juncos Industrial Park;Juncos | December 27, 2000 | |
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide) | Chronic myeloid leukemia | Valeant Pharmaceuticals North America;3300 Hyland Avenue;Costa Mesa, California, 92626 | December 27, 2000 | |
N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody | Pancreatic Cancer | SmithKline Beecham Pharmaceuticals;1250 S. Collegeville Road;Collegeville, Pennsylvania, 19426 | December 7, 2000 | |
Cyclosporine in combination with omega-3 polyunsaturated fatty acids | Prevention of solid organ graft rejection | RTP Pharma Corporation;200 Westpark Corporate Center, 4364 South Alston Avenue;Durham, North Carolina, 27713 | December 6, 2000 | |
Gavilimomab | Graft Versus Host Disease | Amgen;One Amgen Center Drive, Mail Stop 17-2-A;Thousand Oaks, California, 91320 | November 20, 2000 | |
Technetium Tc99m rh-Annexin V | Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants | Theseus Imaging Corporation;124 Mount Auburn Street, Suite 200 North;Cambridge, Massachusetts, 02138 | November 3, 2000 |